Geron Corporation (GERN)

Geron Corporation (GERN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $771M; returns 1 day -0.9%, 1 week -4.3%, 1 year -8.2%.

Geron Corporation is a commercial-stage biopharmaceutical company primarily focused on developing and commercializing therapeutics for hematologic myeloid malignancies, or blood cancers. Its core revenue driver is RYTELO (imetelstat), a first-in-class telomerase inhibitor.

Groups GERN belongs to

• Hematologic Malignancies
• Biopharmaceutical
• Commercial Stage
• Commercial Stage Biotech
• Biotechnology
• Oncology
• Hematology
• Cancer Therapeutics
• Healthcare
• Pharmaceuticals

GERN financial model: income statement, cash flow and balance sheet